Zentalis Pharmaceuticals (ZNTL) Non-Current Assets (2019 - 2026)

Zentalis Pharmaceuticals has reported Non-Current Assets for 8 years, with the latest figure at $35.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 15.0% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $149.8 million (down 20.26% YoY), and the FY2025 full-year result was $35.8 million, down 19.19% from the prior year.
• Non-Current Assets for Q1 2026 stood at $35.0 million, down from $35.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $104.4 million in Q1 2022, with the low at $35.0 million in Q1 2026.
• Average Non-Current Assets over 5 years is $60.5 million, with a median of $53.7 million recorded in 2024.
• Year-over-year, Non-Current Assets soared 374.54% in 2022 and slumped 42.62% in 2023.
• Tracing ZNTL's Non-Current Assets over 5 years: stood at $87.4 million in 2022, then sank by 37.09% to $55.0 million in 2023, then dropped by 19.46% to $44.3 million in 2024, then dropped by 19.19% to $35.8 million in 2025, then declined by 2.25% to $35.0 million in 2026.
• The last three Non-Current Assets figures came in at $35.0 million (Q1 2026), $35.8 million (Q4 2025), and $38.9 million (Q3 2025), per Business Quant data.

Peer Comparison